Alexion, the Rare Disease group of AstraZeneca, have announced it is to invest €65 million in new and enhanced capabilities across its sites in Ireland. The programme will centre on three investments: the installation of new drug substance production equipment and warehousing facilities to support ambient and cold storage at both sites in College Park […]